Study identifier:D419MR00003
ClinicalTrials.gov identifier:NCT06494540
EudraCT identifier:N/A
CTIS identifier:N/A
Prospective non-interventional study (NIS) to examine the effectiveness of Tremelimumab + Durvalumab + platinum chemotherapy (TDC) in patients with metastatic non-squamous NSCLC and high-risk genetic alterations
non-squamous metastatic non-Small-Cell Lung Carcinoma
N/A
No
-
All
600
Observational
18 Years - 120 Years
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Jul 2025 by AstraZeneca
AstraZeneca
-
This prospective, multicenter, non-interventional study (NIS) in Germany aims to collect real-life data of patients with non-squamous (NSQ) metastatic non-small cell lung cancer (mNSCLC) (incl. large cell neuroendocrine carcinoma (LCNEC) if considered NSCLC-like by the treating physician) for whom 1st line treatment initiation with tremelimumab and durvalumab in combination with a platinum-based chemotherapy (TDC) according to marketing authorization was scheduled. The study aims to describe the effectiveness with respect to mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS), Serine/threonine kinase 11 (STK11), Kelch-like ECH-associated protein 1 (KEAP1), and Tumor protein p53 (TP53) as well as expression of Thyroid transcription factor 1 (TTF-1) and Programmed death-ligand 1 (PD-L1) in routine clinical practice. The generated data aims to deepen the understanding of optimal, biomarker-guided treatment strategies for NSQ mNSCLC in distinct subgroups with a high medical need.
Location
Status
Location
Chemnitz, Germany
Status
Recruiting
Location
Georgsmarienhutte, Germany
Status
Recruiting
Location
Berlin, Germany
Status
Recruiting
Location
Hannover, Germany
Status
Recruiting
Location
Munnerstadt, Germany
Status
Recruiting
Location
Goslar, Germany
Status
Recruiting
Location
Herne, Germany
Status
Recruiting
Location
Wiesbaden, Germany
Status
Recruiting
Arms | Assigned Interventions |
---|---|
- |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.